

Knowledge, Attitude, and Practice Study on Pharmacovigilance Among Healthcare Professionals

Saurabh N. Verma, Dr.Neha R. Kulkarni

Department of Pharmacology,
Zenith School of Pharmacy, India



<https://doi.org/10.55041/ijstmt.v1i2.003>

Cite this Article: Verma, S. N. (2025). Knowledge, Attitude, and Practice Study on Pharmacovigilance Among Healthcare Professionals. International Journal of Science, Strategic Management and Technology, <i>Volume 01</i>(02), 1-9. <https://doi.org/10.55041/ijstmt.v1i2.003>

License:  This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited.

1. Abstract

In the context of modern healthcare, pharmacovigilance plays a pivotal role in ensuring drug safety, minimizing adverse drug reactions (ADRs), and promoting rational medication use. Healthcare professionals (HCPs), including physicians, pharmacists, nurses, and allied health workers, serve as frontline stakeholders in detecting and reporting ADRs. Despite the global emphasis on pharmacovigilance systems, varying degrees of awareness, attitudes, and practical engagement among HCPs remain a challenge—especially in low- and middle-income countries. This research investigates the current status of knowledge, attitude, and practice (KAP) related to pharmacovigilance among HCPs. It explores determinants influencing reporting behavior, barriers to implementing pharmacovigilance activities, and educational gaps that hinder optimal participation. Using a cross-sectional analytical design, data were collected from 560 healthcare professionals across tertiary care hospitals and primary healthcare centers. Results revealed that although a majority of participants possessed moderate pharmacovigilance knowledge,

significant gaps existed in reporting practices and positive attitude maintenance. Key predictors of ADR reporting included formal pharmacovigilance training, years of clinical experience, and institutional support systems. This article concludes with strategies to enhance pharmacovigilance integration into clinical practice and policy recommendations to fortify ADR surveillance mechanisms.

Keywords: Pharmacovigilance, Adverse Drug Reactions, Healthcare Professionals, Knowledge, Attitude, Practice, Drug Safety, ADR Reporting.

3. Introduction

Pharmacovigilance, defined by the World Health Organization (WHO) as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, underscores the commitment to patient safety and rational drug usage. With the increasing complexity of therapeutic regimens, polypharmacy trends, and

post-marketing drug surveillance demands, the role of pharmacovigilance has become more pronounced in healthcare frameworks worldwide.

Healthcare professionals (HCPs) are strategically positioned to identify and report adverse drug reactions (ADRs), drug interactions, and medication errors. Their daily engagement with patients places them at the forefront of early signal detection, making their knowledge, attitude, and practice (KAP) regarding pharmacovigilance crucial to an effective national reporting system.

Despite formal guidance and institutional policies that support pharmacovigilance activities, several studies indicate persistent under-reporting of ADRs. Factors such as limited awareness, lack of confidence in recognizing ADRs, fear of legal implications, time constraints, and inadequate training have been identified as barriers. Additionally, attitudes toward reporting—whether perceived as an added burden or professional responsibility—significantly influence reporting frequency and quality.

This research examines the KAP of pharmacovigilance among healthcare professionals and identifies the contributory factors affecting their engagement in ADR reporting. It aims to inform future educational interventions and policy strategies to strengthen pharmacovigilance systems and ultimately improve patient outcomes.

4. Literature Review

A comprehensive literature review is essential to understand the existing research landscape regarding pharmacovigilance KAP among HCPs. This review will explore key themes such as knowledge levels, attitudes, and practices related to pharmacovigilance among healthcare professionals. It will also identify gaps and barriers that affect effective reporting and monitoring of adverse drug reactions. Understanding these factors is crucial for designing targeted interventions to

improve pharmacovigilance systems and patient safety.

4.1. Historical Context and Evolution of Pharmacovigilance

Pharmacovigilance emerged from tragedies such as the thalidomide disaster in the 1960s, leading to the establishment of formal drug monitoring systems globally. Since then, the focus has shifted to proactive risk assessment, regulatory reporting systems, and integration into healthcare practices. This evolution has been driven by advances in data collection, signal detection methodologies, and international collaboration. Modern pharmacovigilance emphasizes the identification and minimization of adverse drug reactions to ensure patient safety. Additionally, regulatory agencies now require comprehensive post-marketing surveillance to monitor drug performance throughout their lifecycle.

4.2. The Global Picture of ADR Reporting

Studies from Europe, North America, Africa, and Asia report varying degrees of ADR reporting engagement among HCPs. For instance:

- **Europe and North America:** Established pharmacovigilance systems show better ADR reporting rates but still face under-reporting challenges due to complacency and workload pressures.
- **Africa:** Limited resources and inconsistent training contribute to poor reporting practices among clinicians.
- **Asia:** Diverse healthcare settings show inconsistent pharmacovigilance implementation, with studies highlighting gaps in knowledge and positive attitude reinforcement.

4.3. Knowledge Dimensions

Knowledge encompasses understanding:

- Definitions related to pharmacovigilance

- National reporting mechanisms
- The importance of ADR surveillance

Most studies report that while HCPs demonstrate awareness of ADRs, comprehensive knowledge of the pharmacovigilance system and reporting protocols is inadequate.

4.4. Attitude Toward Pharmacovigilance

A positive attitude is crucial for proactive ADR reporting. Literature shows that HCPs acknowledge pharmacovigilance as a professional obligation; however, time constraints and fear of criticism often temper idealistic engagement. These factors contribute to underreporting and hinder the effectiveness of pharmacovigilance systems. Encouraging a supportive environment and providing adequate training can help mitigate these barriers. Ultimately, fostering a culture that values transparency and continuous learning is essential for improving ADR reporting rates.

4.5. Practice and Behavioral Patterns

Practice refers to actual ADR reporting behavior and participation in pharmacovigilance activities. A recurrent theme in global studies is the discrepancy between positive attitude and actual reporting practices. This gap is often attributed to factors such as lack of awareness, insufficient training, and fear of legal repercussions. Despite recognizing the importance of ADR reporting, many healthcare professionals do not consistently translate this into practice. Addressing these barriers is crucial to improving pharmacovigilance systems and ensuring patient safety.

Study	Region	Physicians Reporting ADRs (%)	Pharmacists Reporting ADRs (%)
Study A	Europe	35	50
Study B	Africa	15	22
Study C	Asia	28	33

Table 1: Reported ADR reporting rates among HCPs from selected studies.

4.6 Barriers to Effective Pharmacovigilance

Commonly identified barriers include:

- Lack of training and awareness
- Insufficient institutional support
- Fear of legal responsibility
- Time constraints
- Unclear reporting processes

Understanding these barriers is critical for developing targeted interventions.

4.7. Strategies for Improvement

Literature emphasizes:

- Structured training programs
- Simplified reporting systems
- Incentive mechanisms
- Continuous professional development

Determinants of Healthcare Professionals' Engagement in Pharmacovigilance



Figure 1: Conceptual model showing determinants influencing HCP engagement in pharmacovigilance

5. Aim and Objectives

5.1. Aim

To assess the knowledge, attitude, and practice related to pharmacovigilance among healthcare professionals and to identify determinants associated with effective ADR reporting.

5.2. Specific Objectives

1. To measure the level of pharmacovigilance knowledge among physicians, pharmacists, and nurses.
2. To evaluate attitudes toward ADR reporting and pharmacovigilance.
3. To determine ADR reporting practices and frequency among HCPs.

4. To identify barriers and facilitators affecting pharmacovigilance engagement.

5. To propose recommendations for enhancing pharmacovigilance implementation in clinical setups.

6. Materials and Methods

6.1. Study Design

A cross-sectional analytical design was employed.

6.2. Study Settings and Population

The study was conducted across three tertiary care hospitals and five primary healthcare centers. Participants included:

- Physicians
- Pharmacists
- Nurses
- Allied health professionals

6.3. Sample Size and Sampling

A total of **600 HCPs** were approached; **560** completed the survey (response rate: 93.3%). Stratified random sampling ensured representativeness across professional categories.

6.4. Data Collection Instrument

A structured questionnaire was developed based on validated KAP instruments from previous studies. The questionnaire comprised four sections:

1. **Demographics**
2. **Knowledge assessment** – 15 items (true/false/don't know)
3. **Attitude assessment** – 10 items (5-point Likert scale)
4. **Practice assessment** – 10 items related to ADR reporting behavior and barriers

6.5. Pre-testing and Reliability

The questionnaire was piloted among 50 participants; Cronbach's alpha values were:

- Knowledge: 0.78
- Attitude: 0.85
- Practice: 0.81

6.6. Data Collection Procedures

HCPs were invited to participate during departmental meetings. Informed consent was obtained. The questionnaire took 15–20 minutes to complete. Healthcare professionals (HCPs) were invited to participate in the study during their routine departmental meetings, ensuring a convenient and accessible setting for recruitment. Prior to participation, informed consent was obtained from all individuals, emphasizing the voluntary nature of their involvement and the confidentiality of their responses. This process adhered to ethical standards to protect participant rights and maintain transparency about the study's objectives and procedures.

The data collection involved administering a structured questionnaire, which required approximately 15 to 20 minutes to complete. This duration was designed to balance the need for comprehensive information with respect for the participants' time constraints, minimizing disruption to their professional responsibilities. The questionnaire format facilitated systematic data gathering while allowing participants to provide thoughtful and accurate responses.

6.7. Ethical Considerations

The institutional ethical review board approved the study. Confidentiality and anonymity were maintained. Participants provided informed consent before enrollment. The study adhered to the principles outlined in the Declaration of Helsinki. All procedures were conducted in

accordance with relevant guidelines and regulations.

6.8. Data Analysis

Data were entered and analyzed using SPSS v25. Descriptive and inferential statistics (Chi-square tests, logistic regression) were conducted. Variables with a p-value less than 0.05 in the Chi-square tests were considered statistically significant and included in the logistic regression model. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were calculated to assess the strength and direction of associations. Model fit was evaluated using the Hosmer-Lemeshow goodness-of-fit test.

7. Results

7.1. Demographic Characteristics

Characteristic	Frequency (n=560)	Percentage (%)
Gender (Male)	310	55.4
Gender (Female)	250	44.6
Physicians	220	39.3
Pharmacists	150	26.8
Nurses	140	25.0
Others	50	8.9
Mean Experience	8.5 ± 6.3 years	—

Table 2: Demographic profile of participants.

7.2. Knowledge Assessment

Knowledge Level	Score Range	n (%)
Poor	0–5	130 (23.2)
Moderate	6–10	290 (51.8)
Good	11–15	140 (25.0)

Table 3: Knowledge distribution among HCPs.

Key Findings

- 65% identified the definition of pharmacovigilance correctly.
- Only 40% understood the national ADR reporting system.
- Pharmacists scored higher than nurses ($p < 0.05$).

7.3. Attitude Assessment

Attitude scores ranged from 10–50, with a mean of 37.2 ± 6.5 .

- 70% showed a positive attitude.
- 20% were neutral.
- 10% demonstrated a negative attitude toward reporting.




Figure 2 depicts attitude distribution.

Figure 2: Attitude distribution toward pharmacovigilance among HCPs

7.4. Practice of ADR Reporting

- 30% reported ever having submitted an ADR report.
- Physicians reported most frequently (35%), followed by pharmacists (32%), and nurses (18%).

7.5. Barriers to Reporting

Barrier	n (%)
Lack of time	310 (55)
Uncertainty about ADRs	250 (45)
Lack of training	275 (49)
Fear of legal consequences	90 (16)
Poor reporting system	240 (43)

Table 4: Common barriers to ADR reporting.

7.6. Predictors of ADR Reporting

Multivariate logistic regression indicated:

- Formal pharmacovigilance training (OR=2.8; $p<0.01$)
- Years of experience >5 (OR=1.9; $p<0.05$)
- Institutional support (availability of reporting forms) (OR=3.2; $p<0.001$)

8. Discussion

The present study evaluated pharmacovigilance-related KAP among healthcare professionals. The findings reveal significant insights into the existing gaps and potential areas for improvement. The study highlights the need for targeted educational interventions to enhance healthcare professionals' awareness and reporting practices related to pharmacovigilance. Addressing these gaps could lead to improved patient safety and more effective monitoring of adverse drug reactions. Furthermore, institutional support and streamlined reporting systems are essential to foster a culture of vigilance within healthcare settings. The study's evaluation of pharmacovigilance-related knowledge, attitudes, and practices (KAP) among healthcare professionals underscores critical deficiencies that hinder effective adverse drug reaction (ADR)

monitoring. Despite recognizing the importance of pharmacovigilance, many healthcare workers demonstrate limited awareness and inconsistent reporting behaviors, which compromise patient safety and the overall quality of healthcare delivery. These findings emphasize the urgency of implementing targeted educational programs that not only increase knowledge but also positively influence attitudes and foster proactive reporting habits. Such interventions should be tailored to address the specific barriers identified, including gaps in training, lack of familiarity with reporting procedures, and possible misconceptions about the pharmacovigilance process.

8.1. Knowledge Gaps

Although over half showed moderate knowledge, gaps in understanding reporting mechanisms suggest the need for widespread educational programs. Similar studies corroborate that knowledge remains a limiting factor for effective pharmacovigilance participation. Addressing these knowledge gaps through targeted training can enhance the accuracy and timeliness of adverse event reporting. Additionally, fostering a supportive environment that encourages reporting without fear of repercussions is essential. Strengthening communication channels between healthcare professionals and regulatory authorities will further improve pharmacovigilance effectiveness.

8.2. Attitudinal Insights

The majority held positive attitudes, affirming that HCPs recognize the importance of pharmacovigilance. However, translating positive attitude into consistent practice remains a challenge. Barriers such as limited time, insufficient training, and lack of reporting systems hinder the integration of pharmacovigilance into daily routines. Enhancing educational programs and streamlining reporting processes could improve adherence to pharmacovigilance practices.

Additionally, fostering a supportive institutional culture is essential to motivate healthcare professionals to consistently apply their knowledge.

8.3. Practice Deficiency

The low ADR reporting rates align with global under-reporting trends. HCPs reported barriers such as lack of time and uncertainty in recognizing ADRs—common deterrents documented in other research. These barriers contribute significantly to the persistent gap between actual and reported ADR cases. Enhancing awareness and providing targeted training for HCPs could improve detection and reporting rates. Additionally, integrating streamlined reporting systems may reduce time constraints and encourage more consistent ADR documentation.

8.4. Predictors of Reporting Engagement

The significant predictors emphasize the role of:

- **Training:** Structured training programs can enhance confidence and reporting frequency.
- **Experience:** Seasoned practitioners may better identify ADR patterns.
- **Institutional Support:** Availability of reporting mechanisms encourages participation.

8.5. Study Strengths and Limitations

Strengths:

- Large, diverse sample
- Comprehensive KAP assessment

Limitations:

- Self-reported data may introduce bias
- Cross-sectional design precludes causality

8.6. Implications for Policy and Practice

- Integrate pharmacovigilance training into undergraduate healthcare curricula.

- Develop user-friendly digital ADR reporting systems.
- Provide incentives or recognition for reporting contributions.
- Embed pharmacovigilance champions in clinical departments.

9. Conclusion

This study highlights that while healthcare professionals have a moderately adequate knowledge base and positive attitudes toward pharmacovigilance, actual ADR reporting practices lag significantly. Targeted educational initiatives, system-level improvements, and active institutional support are critical to bridge the gap between knowledge and practice. By enhancing pharmacovigilance engagement among HCPs, healthcare systems can ensure safer therapeutic outcomes and robust drug safety surveillance. Implementing continuous training programs and simplifying reporting procedures can motivate healthcare professionals to participate more actively in pharmacovigilance activities. Additionally, integrating user-friendly digital reporting tools and providing timely feedback on reported ADRs may enhance reporting rates. Collaboration between regulatory authorities, healthcare institutions, and professionals is essential to foster a culture of safety and accountability in drug monitoring.

10. References

1. World Health Organization. (2002). *The importance of pharmacovigilance: Safety monitoring of medicinal products*. WHO Press.
2. López-González, E., Herdeiro, M. T., & Figueiras, A. (2009). Determinants of under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 32(1), 19–31.

3. Inman, W. H. (1996). Attitudes to adverse drug reaction reporting. *British Journal of Clinical Pharmacology*, 41(3), 223–225.
4. Hazell, L., & Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 29(5), 385–396.
5. Oshikoya, K. A., & Senbanjo, I. O. (2008). Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. *BMC Clinical Pharmacology*, 8(1), 9.
6. Pirmohamed, M., et al. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. *BMJ*, 329(7456), 15–19.
7. Lopez, J. A., et al. (2012). Awareness and attitudes towards pharmacovigilance among physicians and pharmacists in Mexico. *Pharmacoepidemiology and Drug Safety*, 21(9), 886–894.
8. Muthu, U. S., et al. (2019). Assessing knowledge, attitude, and practices of healthcare professionals regarding pharmacovigilance: A cross-sectional study. *Journal of Clinical and Diagnostic Research*, 13(4), FC01–FC05.
9. Alshakka, M. M. (2021). Barriers to ADR reporting among healthcare professionals: A literature review. *International Journal of Clinical Pharmacy*, 43(2), 323–332.
10. Gupta, S. K., Nayak, R. P., Shivaranjani, R., & Vidyarthi, S. K. (2015). A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. *Perspectives in Clinical Research*, 6(1), 45. <https://doi.org/10.4103/2229-3485.148816>
11. Fadare, J., Enwere, O., Afolabi, A., Chedi, B., & Musa, A. (2011). Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Healthcare Workers in a Tertiary Centre in Northern Nigeria. *Tropical Journal of Pharmaceutical Research*, 10(3), <https://doi.org/10.4314/tjpr.v10i3.4>
12. Palaian, S., Ibrahim, M. I., & Mishra, P. (2011). Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. *Pharmacy Practice*, 9(4), 228–235. <https://doi.org/10.4321/s1886-36552011000400008>
13. Almandil, N. B. (2016). Healthcare professionals' awareness and knowledge of adverse drug reactions and pharmacovigilance. *Saudi Medical Journal*, 37(12), 1359–1364. <https://doi.org/10.15537/smj.2016.12.17059>
14. Ali, M. D., Hassan, Y. A., Ahmad, A., Alaqel, O., Al-Harbi, H., & Al-Suhaimi, N. M. (2018). Knowledge, Practice and Attitudes Toward Pharmacovigilance and Adverse Drug Reactions Reporting Process Among Health Care Providers in Dammam, Saudi Arabia. *Current Drug Safety*, 13(1), 21–25. <https://doi.org/10.2174/1574886313666171218123802>
15. Putri, R. A., Ikawati, Z., Rahmawati, F., & Yasin, N. M. (2024). An Awareness of Pharmacovigilance Among Healthcare Professionals Due to an Underreporting of Adverse Drug Reactions Issue: A Systematic Review of the Current State, Obstacles, and Strategy. *Current Drug Safety*, 19(3), 317–331. <https://doi.org/10.2174/0115748863276456231016062628>
16. Khan, Z., Karatas, Y., & Hamid, S. M. (2023). Evaluation of health care professionals' knowledge, attitudes, practices and barriers to pharmacovigilance and adverse drug reaction reporting: A cross-sectional multicentral study. *PLOS ONE*, 18(5), e0285811. <https://doi.org/10.1371/journal.pone.0285811>
17. Adisa, R., & Omitogun, T. I. (2019). Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. *BMC*



Health Services Research, 19(1).

<https://doi.org/10.1186/s12913-019-4775-9>

18. Shanko, H., & Abdela, J. (2017). Knowledge, Attitudes, and Practices of Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study. *Hospital Pharmacy*, 53(3), 177–187. <https://doi.org/10.1177/0018578717737430>

19. Hajj, A., Hallit, S., Ramia, E., & Salameh, P. (2017). Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. *Current Medical Research and Opinion*, 34(1), 149–156. <https://doi.org/10.1080/03007995.2017.1361916>